Neutropenia associated with long-term ceftaroline use

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 264-269

  LaVie, Katherine W ^a,c   Anderson, Scott W ^a,d   O'Neal, Hollis R ^a   Rice, Todd W ^b   Saavedra, Tatiana C ^a   O'Neal, Catherine S ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; INFECTION; LONG TERM CARE; MALE; MEDICAL RECORD; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LEUKOCYTE COUNT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; STAPHYLOCOCCAL INFECTIONS; TIME FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS;

EID: 84957895343     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01471-15     Document Type: Article

References (27)

1. Boucher HW, Corey GR. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46(Suppl 5):S344-S349.
2. Magana M, Ioannidis A, Magiorkinis E, Ursu O, Bologa CG, Chatzipanagiotou S, Hamblin MR, Tegos GP. 2015. Therapeutic options and emerging alternatives for multidrug resistant staphylococcal infections. Curr Pharm Des 21:2058-2072. http://dx.doi.org/10.2174/1381612821666150310101851.
3. Drusano GL. 2010. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved antimethicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother 65(Suppl 4):iv33-iv39.
4. Jacqueline C, Amador G, Batard E, LeMabecque V, Potel G, Caillon J. 2012. Antibiotics against endocarditis - past, present and future (experimental data), p 97-124. In Breijo-Marquez PFR (ed), Endocarditis. InTech, Rijeka, Croatia.
5. Bazan JA, Martin SI, Kaye KM. 2011. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Med Clin North Am 95:743-760, viii. http://dx.doi.org/10.1016/j.mcna.2011.03.009.
6. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, Peters G. 2012. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 39:96-104. http://dx.doi.org/10.1016/j.ijantimicag.2011.09.028.
7. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculi T. 2010. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv41-iv51.
8. File TM, Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA. 2011. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(Suppl 3):iii19-iii32.
9. Low DE, File TM, Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA. 2011. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(Suppl 3):iii33-iii44.
10. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. 2010. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv53-iv65.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8.
12. Lang R, Lishner M, Ravid M. 1991. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. Rev Infect Dis 13:68-72. http://dx.doi.org/10.1093/clinids/13.1.68.
13. Wallerstein RO, Condit PK, Kasper CK, Brown JW, Morrison FR. 1969. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 208:2045-2050.
14. Cunha BA. 2001. Antibiotic side effects. Med Clin North Am 85:149-185. http://dx.doi.org/10.1016/S0025-7125(05)70309-6.
15. Andrès E, Maloisel F. 2008. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 15:15-21. http://dx.doi.org/10.1097/MOH.0b013e3282f15fb9.
16. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-e93. http://dx.doi.org/10.1093/cid/cir073.
17. Wright AJ. 1999. The penicillins. Mayo Clin Proc 74:290-307. http://dx.doi.org/10.4065/74.3.290.
18. Mandell GL, Bennett JE, Dolin R. 2010. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. Churchill Livingstone/Elsevier, Philadelphia, PA.
19. Wong BB, Ko GJ. 2003. Neutropenia in patients receiving long-term cefepime therapy for osteomyelitis. Am J Health Syst Pharm 60:2229-2232.
20. Murphy MF, Chapman JF, Metcalfe P, Waters AH. 1985. Antibiotic-induced neutropenia. Lancet ii:1306-1307.
21. File TM, Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D. 2010. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 51:1395-1405. http://dx.doi.org/10.1086/657313.
22. Rimawi RH, Frenkel A, Cook PP. 2013. Ceftaroline - a cause for neutropenia. J Clin Pharm Ther 38:330-332. http://dx.doi.org/10.1111/jcpt.12062.
23. Yam FK, Kwan BK. 2014. A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline. Am J Health Syst Pharm 71:1457-1461. http://dx.doi.org/10.2146/ajhp130474.
24. Jain R, Chan JD, Rogers L, Dellit TH, Lynch JB, Pottinger PS. 2014. High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy 34:758-763. http://dx.doi.org/10.1002/phar.1435.
25. Radley DC, Finkelstein SN, Stafford RS. 2006. Off-label prescribing among office-based physicians. Arch Intern Med 166:1021-1026. http://dx.doi.org/10.1001/archinte.166.9.1021.
26. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:1-38.
27. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, Kunkel MJ, Yancey RW, Williams DN. 2004. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 38:1651-1672. http://dx.doi.org/10.1086/420939.